To hear about similar clinical trials, please enter your email below
Trial Title:
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
NCT ID:
NCT05871762
Condition:
Rectal Neoplasms
Conditions: Official terms:
Rectal Neoplasms
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Registry study, no specific intervention
Description:
Registry study, no specific intervention
Summary:
The purpose of this study is to compare the efficacy, prognosis, health economics of
different treatment modalities of mid-low rectal cancer in different centers in China,
and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to
explore the best treatment modality that meets the actual need of medical units in each
region and at each level. The investigators hope to provide evidence-based medical
suggestions for medical quality control of rectal cancer and revision of clinical
guidelines, and provides a source of decision making for medical management and medical
insurance.
Criteria for eligibility:
Study pop:
mid-low rectal cancer patients
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- pathologically confirmed rectal adenocarcinoma
- located within 12cm below the anal verge
Exclusion Criteria:
- diagnosed with distant metastasis
- multiple primary colorectal cancers
- history of previous malignant tumors
- Pregnant or lactating women
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Peking Union Medical College Hospital
Address:
City:
Beijing
Zip:
100730
Country:
China
Status:
Recruiting
Contact:
Last name:
Xiao Yi
Phone:
+86 13366036387
Email:
xiaoy@pumch.cn
Start date:
June 4, 2023
Completion date:
May 17, 2027
Lead sponsor:
Agency:
Peking Union Medical College Hospital
Agency class:
Other
Source:
Peking Union Medical College Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05871762
